<i>In vitro</i> activity of nine antimicrobials against pneumococci isolated from relapses and reinfections

Clinical Laboratory Standard Institute (CLSI) breakpoints: aPenicillin oral breakpoints: susceptible ≤0.06 mg/L, intermediate 0.12–1 mg/L and resistant ≥2 mg/L. bPenicillin parenteral (non-meningitis) breakpoints: susceptible ≤2 mg/L, intermediate 4 mg/L and resistant ≥8 mg/L. cCefotaxime (meningitis) breakpoints: susceptible ≤0.5 mg/L, intermediate 1 mg/L and resistant ≥2 mg/L. dCefotaxime parenteral (non-meningitis) breakpoints: susceptible ≤1 mg/L, intermediate 2 mg/L and resistant ≥4 mg/L. eNon-susceptibility to ciprofloxacin breakpoint MIC ≥4 mg/L and susceptibility breakpoint ≤2 mg/L. fP-value comparing susceptible strains.